

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087739 A1

(51) International Patent Classification⁷: C07K 1/113,
19/00

(21) International Application Number:
PCT/KR2004/000781

(22) International Filing Date: 3 April 2004 (03.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2003-0021122 3 April 2003 (03.04.2003) KR

(71) Applicant (for all designated States except US): HANMI
PHARM. CO. LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-
myeon, 445-910 Hwaseong-gun, Kyungki-do (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Young Min
[KR/KR]; Maehwamaeul Woonam Dreamvalley 102-803,
#877, Gomae-ri, Kiheung-eup, 449-900 Yongin-si,
Kyungki-do (KR). KIM, Dae Jin [KR/KR]; Gubango
Apt. 28-402, Banpobon-dong, Seocho-gu, 137-049 Seoul
(KR). BAE, Sung Min [KR/KR]; 303-ho, #1587-8,

Bongcheon-4-dong, Kwanak-gu, 151-054 Seoul (KR).
LIM, Chang Ki [KR/KR]; #20, Kumi-dong, Bundang-gu,
463-500 Seongnam-si, Kyungki-do (KR). KIM, Kyeong
Bae [KR/KR]; #100-435, Bongcheon-6-dong, Kwanak-gu,
151-810 Seoul (KR). KWON, Se Chang [KR/KR];
Hyundai 8-cha 802-2205, Kwangjang-dong, Kwangjin-gu,
143-815 Seoul (KR). LEE, Gwan Sun [KR/KR];
Woosung Apt. 3-404, Okeum-dong, Songpa-gu, 138-739
Seoul (KR).


(74) Agents: JANG, Seongku et al.; 19th Fl., KEC Building,
#275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: PEG-PHYSIOLOGICALLY ACTIVE POLYPEPTIDE HOMODIMER COMPLEX HAVING PROLONGED IN VIVO
HALF-LIFE AND PROCESS FOR THE PREPARATION THEREOF



(57) Abstract: A PEG-polypeptide homodimer complex, which comprises a PEG linker and two molecules of a physiologically active polypeptide, wherein the two molecules of the physiologically active polypeptide are connected via the PEG linker, and each of the two molecules of the physiologically active polypeptide is modified with one molecule of PEG, is useful for the development of a polypeptide drug having a prolonged half-life in the blood.



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.